Liquidia posts strong Q3 sales and adjusted EBITDA growth, but GAAP loss driven by $389.7M settlement charge
Liquidia Corporation reported third‑quarter 2026 net product sales of $222.7 million, a 31% sequential increase, and adjusted EBITDA of $140.5 million, marking five straight quarters of growth. The quarter showed a GAAP net loss of $236.3 million, caused by a one‑time $389.7 million litigation settlement with United Therapeutics. Cash and cash equivalents stood at $396.1 million at quarter end.
Why it matters
The company’s operating performance suggests a rapidly scaling business, but the large settlement charge creates a GAAP loss that may affect earnings‑per‑share metrics and short‑term valuation. The settlement removes all litigation risk and secures continued access to YUTREPIA for patients, which could support future revenue growth.
Key facts
- 1Net product sales of YUTREPIA were $222.7 million in Q3 2026, up 31% sequentially. quantisnow.com
- 2Adjusted EBITDA (non‑GAAP) was $140.5 million, the fifth consecutive quarterly increase. quantisnow.com
- 3GAAP net loss for the quarter was $236.3 million. quantisnow.com
- 4The loss included a $389.7 million litigation settlement charge with United Therapeutics. quantisnow.com
- 5Cash and cash equivalents were $396.1 million prior to settlement payments. quantisnow.com
- 6GAAP EPS was a loss of $2.64 per share. seekingalpha.com
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.